Precision Oncology: Emerging Technologies & Implementation
Jan 12–15, 2025 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
John D. Carpten, David Solit and Chanita H Hughes Halbert
In Person
On Demand
Jan 12–15, 2025 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
John D. Carpten, David Solit and Chanita H Hughes Halbert
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, January 12, 2025
Booking Function
Registration
4:00–8:00 PM
Colorado Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Colorado Ballroom Foyer
Monday, January 13, 2025
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome and Keynote Address
8:00–9:00 AM
Peaks 4 & 5
* John D. Carpten, City of Hope Cancer Center
Session Chair
Session Chair
Elaine R Mardis, Nationwide Children's Hospital
Complex Molecular Characterization of Pediatric Cancers: Setting the Stage for Precision Diagnosis and Therapy
Complex Molecular Characterization of Pediatric Cancers: Setting the Stage for Precision Diagnosis and Therapy
Targeted Therapeutics
9:00–11:15 AM
Peaks 4 & 5
Frank S McCormick, University of California, San Francisco
Targeting Ras in Human Cancer
Targeting Ras in Human Cancer
* Christine Lovly, Vanderbilt University
Sensitivity and Resistance to Kinase Inhibitors in Cancer
Sensitivity and Resistance to Kinase Inhibitors in Cancer
* Lillian L Siu, Princess Margaret Cancer Centre
Targeted Cytotoxics: Advances in Antibody Drug Conjugates
Targeted Cytotoxics: Advances in Antibody Drug Conjugates
Hee Won Yang, Columbia University
Short Talk: Deciphering the Mechanism Underlying Resistance to pan-RAS Inhibitors
Short Talk: Deciphering the Mechanism Underlying Resistance to pan-RAS Inhibitors
Jeff Perry, City of Hope
Short Talk: Small Molecule-Based Targeting of PCNA Protein to Develop a Cancer-Selective Chemotherapy
Short Talk: Small Molecule-Based Targeting of PCNA Protein to Develop a Cancer-Selective Chemotherapy
Coffee Break
9:30–9:50 AM
Colorado Ballroom Foyer
Poster Setup
11:15–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:15–4:30 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Clinical Trial Advances/Insights/Design
5:00–6:45 PM
Peaks 4 & 5
David Solit, Memorial Sloan Kettering Cancer Center
Lessons from the Study of Exceptional Responders
Lessons from the Study of Exceptional Responders
* Vivek Subbiah, Sarah Cannon Research Institute
New Clinical Trial Designs for the Precision Medicine Era
New Clinical Trial Designs for the Precision Medicine Era
Sunantha Sethuraman, Repare Therapeutics
Short Talk: Utility of Circulating Tumor DNA (Ctdna) to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib (Lunre) Alone or in Combination with the ATR Inhibitor Camonsertib (Cam) in the MYTHIC Phase I Trial
Short Talk: Utility of Circulating Tumor DNA (Ctdna) to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib (Lunre) Alone or in Combination with the ATR Inhibitor Camonsertib (Cam) in the MYTHIC Phase I Trial
Social Hour with Lite Bites
6:45–7:45 PM
Peaks 1 - 3
Poster Session 1
7:15–10:00 PM
Peaks 1 - 3
Tuesday, January 14, 2025
Breakfast
7:00–8:00 AM
Summit Gallery
Precision Oncology and Disparities (Implementation and Discovery)
8:00–11:00 AM
Peaks 4 & 5
Rizwana Mia, South African Medical Research Council
Remote Presentation: Precision Oncology Disparities in South Africa
Remote Presentation: Precision Oncology Disparities in South Africa
Rick Kittles, Morehouse School of Medicine
Reimagining Health Equity in the Era of Precision Medicine
Reimagining Health Equity in the Era of Precision Medicine
Clayton C. Yates, Johns Hopkins School of Medicine
Using Precision Oncology to Support Innovation in Prostate Cancer Equity
Using Precision Oncology to Support Innovation in Prostate Cancer Equity
* Chanita H Hughes Halbert, University of Southern California
Intersection Between Social and Biological Risk Factors on the Pathway to Cancer Health Equity
Intersection Between Social and Biological Risk Factors on the Pathway to Cancer Health Equity
Nick Pannunzio, University of Califormia Irvine
Short Talk: Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities
Short Talk: Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities
Lixing Yang, University of Chicago
Short Talk: Data-Driven Drug Discovery Targeting Transcription and Replication Collision in Cancer
Short Talk: Data-Driven Drug Discovery Targeting Transcription and Replication Collision in Cancer
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Poster Setup
11:00–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:00–1:30 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Symposia Spotlight: Late-Breaking research presentations selected from abstract submissions
2:00–3:15 PM
Peaks 4 & 5
* Clayton C. Yates, Johns Hopkins School of Medicine
Session Chair
Session Chair
Tomas Babak, Leapfrog Bio
EP300 Loss of Function is a Pan-Cancer Sensitizer to BET Inhibition
EP300 Loss of Function is a Pan-Cancer Sensitizer to BET Inhibition
Yaniv Kazansky, Weill Cornell Medicine
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Luke Pike, Memorial Sloan Kettering Cancer Center
EGFR Alteration Subtype Predicts the Benefit Of Stereotactic Radiosurgery in Patients with NSCLC Brain Metastasis
EGFR Alteration Subtype Predicts the Benefit Of Stereotactic Radiosurgery in Patients with NSCLC Brain Metastasis
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai
RAF/MEK Glue Mechanism on RAF Enables RAS Mutant Tumor-Selective Therapy
RAF/MEK Glue Mechanism on RAF Enables RAS Mutant Tumor-Selective Therapy
Career Roundtable
3:30–4:30 PM
Peaks 4 & 5
Clayton C. Yates, Johns Hopkins School of Medicine
Professor
Professor
Manisha Rao, AstraZeneca
Senior Scientist
Senior Scientist
Peter W. Szlosarek, Barts Cancer Institute
Professor & Group Leader, Physician Scientist
Professor & Group Leader, Physician Scientist
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Precision Immuno-oncology / Overcoming Immune Evasion Through Combination Therapies
5:00–7:00 PM
Peaks 4 & 5
* David Solit, Memorial Sloan Kettering Cancer Center
Session Chair
Session Chair
Padmanee Sharma, University of Texas MD Anderson Cancer Center
Advancing Immune Checkpoint Targets in Cancer
Advancing Immune Checkpoint Targets in Cancer
Marta Luksza, Icahn School of Medicine at Mount Sinai
Novel Computational Methods to Define Immunotherapy Sensitivity
Novel Computational Methods to Define Immunotherapy Sensitivity
Alona Sosinsky, Genomics England
Integrating Genome Sequencing into Clinical Practice for Cancer Patients
Integrating Genome Sequencing into Clinical Practice for Cancer Patients
Christine Yeh, Stanford University
Short Talk: Mapping Spatial Organization and Genetic Cell-State Regulators to Target Immune Evasion in Ovarian Cancer
Short Talk: Mapping Spatial Organization and Genetic Cell-State Regulators to Target Immune Evasion in Ovarian Cancer
Kyuson Yun, Houston Methodist/Weill Cornell Medical College
Short Talk: A Novel Functional Precision Oncology Platform Technology: E-Slice with Intact TME for Immunotherapy and Other Cancer Therapy Response Measurements from Human Tumors
Short Talk: A Novel Functional Precision Oncology Platform Technology: E-Slice with Intact TME for Immunotherapy and Other Cancer Therapy Response Measurements from Human Tumors
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Poster Session 2
7:30–10:00 PM
Peaks 1 - 3
Wednesday, January 15, 2025
Breakfast
7:00–8:00 AM
Summit Gallery
Technologies for Biomarker Discovery (Discovery Through Application in the Clinic)
8:00–11:00 AM
Peaks 4 & 5
* Christina Curtis, Stanford University
Genomic, Immune and Microenvironmental Biomarkers in Breast Cancer
Genomic, Immune and Microenvironmental Biomarkers in Breast Cancer
* Colin D. Weekes, Massachusetts General Hospital
Harnessing Tumor Plasticity for Therapeutic Intent
Harnessing Tumor Plasticity for Therapeutic Intent
Ericca Stamper, Dovetail Genomics, Part of Cantata Bio LCC
Short Talk: Linkprep™ – A Comprehensive Assay for Cancer Genome Characterization that Enables Ultra-Sensitive Detection of Structural Variants
Short Talk: Linkprep™ – A Comprehensive Assay for Cancer Genome Characterization that Enables Ultra-Sensitive Detection of Structural Variants
Emily Madden, EpiCypher, Inc
Short Talk: Chromatin Profiling from Formalin-Fixed Paraffin-Embedded Samples for Biomarker Discovery
Short Talk: Chromatin Profiling from Formalin-Fixed Paraffin-Embedded Samples for Biomarker Discovery
Oliver Jonas, Brigham & Women's Hospital
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Short Talk: Clinical Implementation of Implantable Microdevices to Identify Highly Effective Treatment Combinations in Cancer Patients
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–4:30 PM
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Data Science, Informatics, AI & Machine Learning
5:00–6:45 PM
Peaks 4 & 5
Eliezer M. Van Allen, Dana-Farber Cancer Institute
Remote Presentation: Convergence of Machine Learning and Multi-omics for Precision Cancer Medicine
Remote Presentation: Convergence of Machine Learning and Multi-omics for Precision Cancer Medicine
* David Craig, City of Hope
Informatics Strategies for Incorporating Genetic Ancestry in Precision Oncology
Informatics Strategies for Incorporating Genetic Ancestry in Precision Oncology
Benjamin Greenbaum, Memorial Sloan Kettering Cancer Center
Learning what the Immune System Senses in Cancer and When It Matters
Learning what the Immune System Senses in Cancer and When It Matters
John Paul Shen, University of Texas MD Anderson
Short Talk: Utilizing an Automated, NLP-aided Platform to Generate Large (>10,000 patient), Comprehensive Clinical & Molecular Datasets to Enable a Real-World Evidence Approach to Precision Oncology
Short Talk: Utilizing an Automated, NLP-aided Platform to Generate Large (>10,000 patient), Comprehensive Clinical & Molecular Datasets to Enable a Real-World Evidence Approach to Precision Oncology
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Peaks 4 & 5
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Cash Bar
8:00–9:00 PM
Peaks 1 - 3
Entertainment
8:00–9:00 PM
Peaks 4 - 5
Thursday, January 16, 2025
Fundraising
Departure
12:00–11:59 PM
Subscribe for Updates